Vericel price target raised to $56 from $53 at BTIG

BTIG raised the firm’s price target on Vericel to $56 from $53 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in MedTech. Large-cap quality stocks should be “best positioned” as increasing geopolitical risks and the fear of “monetary policy stasis” with higher for longer interest rates has investors largely concentrated in large-cap, quality growth names, and these companies are likely best positioned to outperform as investors ride out the macro environment, the analyst tells investors in a research note.